Who owns SUTRO BIOPHARMA, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of STRO from SEC Form 13F filings across 97 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 97 institutions disclosed 16.5M shares of SUTRO BIOPHARMA, INC. worth $545.7M — about 99.4% of shares outstanding; the largest disclosed holder is PERCEPTIVE ADVISORS LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
97
13F holders
$545.7M
value, 2026 filers
99.4%
of shares outstanding (16.5M sh)
41
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of STRO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 1.3M | $43.3M | 0.7% | 7.9% | +82.4% |
| 2 | BVF INC/IL | 1.3M | $41.6M | 1.1% | 7.6% | 0.0% |
| 3 | Affinity Asset Advisors, LLC | 1.2M | $38.9M | 1.8% | 7.1% | +9.6% |
| 4 | BlackRock, Inc. | 1.1M | $37.3M | 0.0% | 6.8% | +382.5% |
| 5 | SAMSARA BIOCAPITAL, LLC | 1.1M | $35.3M | 2.9% | 6.4% | 0.0% |
| 6 | Kynam Capital Management, LP | 872,558 | $29.0M | 1.6% | 5.3% | 0.0% |
| 7 | ORBIMED ADVISORS LLC | 743,944 | $24.7M | 0.5% | 4.5% | -7.1% |
| 8 | Balyasny Asset Management L.P. | 711,162 | $23.6M | 0.0% | 4.3% | +52.7% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 694,219 | $23.0M | 0.0% | 4.2% | -3.6% |
| 10 | EVENTIDE ASSET MANAGEMENT, LLC | 585,262 | $19.4M | 0.3% | 3.5% | -18.2% |
| 11 | Velan Capital Investment Management LP | 512,160 | $17.0M | 10.4% | 3.1% | 0.0% |
| 12 | Woodline Partners LP | 458,029 | $15.2M | 0.0% | 2.8% | +0.1% |
| 13 | ADAR1 Capital Management, LLC | 404,014 | $13.4M | 0.6% | 2.4% | -23.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 389,692 | $12.9M | 0.0% | 2.4% | +127.4% |
| 15 | ACADIAN ASSET MANAGEMENT LLC | 373,839 | $12.4M | 0.0% | 2.3% | +11.3% |
| 16 | MILLENNIUM MANAGEMENT LLC | 365,972 | $12.2M | 0.0% | 2.2% | +74.0% |
| 17 | STATE STREET CORP | 305,979 | $10.2M | 0.0% | 1.8% | +487.1% |
| 18 | Merck & Co., Inc.NEW | 272,351 | $9.0M | 1.7% | 1.6% | new |
| 19 | ACUTA CAPITAL PARTNERS, LLC | 270,251 | $9.0M | 6.3% | 1.6% | +0.3% |
| 20 | AMERIPRISE FINANCIAL INCNEW | 244,669 | $8.1M | 0.0% | 1.5% | new |
| 21 | Point72 Asset Management, L.P. | 237,827 | $7.9M | 0.0% | 1.4% | -65.6% |
| 22 | KVP Capital Advisors, LP | 226,575 | $7.5M | 5.5% | 1.4% | 0.0% |
| 23 | UBS Group AG | 208,512 | $6.9M | 0.0% | 1.3% | -46.9% |
| 24 | TWO SIGMA INVESTMENTS, LP | 201,688 | $6.7M | 0.0% | 1.2% | +209.5% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLCNEW | 197,562 | $6.6M | 0.0% | 1.2% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.